Navigation Links
Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes
Date:7/21/2011

position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 24 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, a sanofi company, plans to commercialize Isis' lead product, mipomersen, in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of Isis' antisense inhibitors of PTP-1B including ISIS-PTP1BRx and planned commercialization of mipomersen.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual rep
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
6. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. Prolexys Pharmaceuticals Initiates Phase 1 Study
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... FARMINGDALE, N.Y. , Oct. 30, 2014  Misonix, ... surgical device company that designs, manufactures and markets innovative ... surgical specialties, announced today that it will report financial ... Thursday, November 6, 2014. The Company has scheduled a ... at 4:30 pm ET to review the results. ...
(Date:10/30/2014)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology, and medical device industries, ... the United States , today announced ... Tel Aviv area of Israel.  ... platform of integrated R&D services to local customers. It ...
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4
... Inc.,("CeloNova"), leading and accelerating healthcare solutions through ... breakthrough,results from the ATLANTA study of the ... the 20th Annual International Symposium on,Endovascular Therapy ... Corrado Tamburino, MD, President of the ...
... Ortho Women,s Health,& Urology(TM), Division of ... for ORTHO EVRA(R),(norelgestromin/ethinyl estradiol transdermal system) to ... includes two new additional estimates of relative,risk ... of 1.1,(indicating no increase in risk) and ...
Cached Medicine Technology:CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F 2ORTHO EVRA(R) Prescribing Information Updated 2ORTHO EVRA(R) Prescribing Information Updated 3
(Date:10/30/2014)... Tanaka and her research group at the DFG Research ... at the TU Dresden (CRTD) demonstrated for the first ... spinal cord in three dimensions from mouse embryonic stem ... dorsal interneurons along the dorsal/ventral axis was observed., This ... " Stem Cell Reports " on 30.10.2014 ., ...
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer ... and more, is currently hosting a sweepstakes on its ... is open to U.S. residents age 18 and over, ... One lucky winner will then be selected at random ... card to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba ...
(Date:10/30/2014)... 2014 Graphics, coding, typography and search ... the craft of web design and require thorough knowledge ... simpler solution to create a website can be as ... information, customer reviews and Facebook posts all accumulate on ... the next evolution of how a business can develop ...
(Date:10/30/2014)... Calif. (PRWEB) October 30, 2014 ... mutually exclusive concepts in the medical-grade skin care ... the development of uniquely potent topical dermatological products, ... System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant ... glycolic acid concentrations (50% and 70%) and a ...
(Date:10/30/2014)... PreDiabetes Centers , the pioneer ... shoppers with a supply of sugardown®, a chewable dietary ... blood sugar spikes. Learning how to control blood sugar ... of a diabetes prevention plan. , Shoppers who spend ... tube of sugardown. The offer expires November 30. ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2
... , , , NEW YORK, June 10 Vendome ... magazines and producers of the HEALTHCARE DESIGN.09 Conference announces the 2009 ... those who are unable to afford the cost of the conference ... fee. , , "We believe, as a company ...
... condition in which patients, aortic valves have just two leaflets instead ... up to two percent of the general population. The defect ... the valve and may results in a feeling of tightness in ... is easily diagnosed; often physicians can hear a "click" or a ...
... vomiting disease invades cells by attaching to particular sugar ... the conclusion of a thesis presented at the Sahlgrenska ... an important step in the development of a drug ... Winter vomiting disease is an infectious inflammation ...
... Illinois, USA June 10, 2009 The most important ... are the types of diagnostic tests performed and whether or ... they can ensure that only patients who need readily accessible ... study published today in the Journal of Hospital Medicine ...
... search platform to enable healthcare professionals to find Medicare ... 10 Vivisimo ( www.vivisimo.com ), a ... provider of education and information on healthcare regulatory compliance ... platform to power search on ...
... Organizations team pilot chronic care management tools in a ... Microsoft Corp., in collaboration with the University ... Family Medicine and Community Health, the city of Miami, ... in Miami,s Overtown neighborhood aimed at changing the way ...
Cached Medicine News:Health News:HEALTHCARE DESIGN.09 Announces Scholarship Program 2Health News:First-degree relatives of patients with bicuspid aortic valve should be screened 2Health News:Drugs against winter vomiting disease one step closer 2Health News:Availability of diagnostic tests drive success in hospitalist-run short-stay units 2Health News:HCPro Selects Vivisimo Velocity to Launch MedicareFind.com 2Health News:HCPro Selects Vivisimo Velocity to Launch MedicareFind.com 3Health News:The University of Miami Miller School of Medicine, the City of Miami, Microsoft and Resolute Solutions Seek to Improve Care of Diabetic Populations Using Collaborative Technology 2Health News:The University of Miami Miller School of Medicine, the City of Miami, Microsoft and Resolute Solutions Seek to Improve Care of Diabetic Populations Using Collaborative Technology 3
... IOL is a foldable silicone IOL. It ... and is designed to be inserted with ... Multifocal IOL is the first and only ... offer patients a full range of functional ...
1% Sodium Hyaluronate, 10mg/mL, sterile opthalmic injection...
... Ocucoat is a 2% Hydroxypropyl Methylcellulose solution ... surgeons performing high volume, small incision surgery. ... allows for rapid removal with minimal risk ... Ocucoat permits an unobstructed view of the ...
... Amvisc is the right viscoelastic agent for ... the planned extracap technique. Amvisc possesses sufficient ... removal. Amvisc is highly cohesive so that ... case is easily and quickly accomplished. Amvisc ...
Medicine Products: